Science

SiSaf’s Bio-Courier technology combines a proprietary bioabsorbable silicon matrix with surface lipids and amino acids, a structure that addresses several of the major limitations and concerns associated with lipid nanoparticles to deliver RNA therapeutics.

Silicon’s durable electrostatic potential helps bind and stabilise RNA reducing the need for potentially toxic cationic lipids and averting the risk of premature detachment of RNA.

The high structural integrity of the silicon metalloid matrix prevents collapse on freeze drying and reduces the need for PEGylation, a key step to avoid the need for ultra-cold supply chain storage.

Bio-Courier® Technology

The Solution

SiSaf’s Bio-Courier technology addresses the challenges of lipid nanoparticles by stabilizing both lipids and RNA through a bioabsorbable silicon matrix.

   Silicon’s positive charge and high ζ-potential electrostatically bind and condense RNA preventing the premature disassociation of RNA and reducing the reliance on cationic lipids.

   High volumes of tightly condensed RNA are electrostatically bonded to the silicon matrix, protecting them from hydrolysis to prolong their systemic survival.

    The structural integrity of the Silicon metalloid prevents physical collapse of the particle permitting lyophilisation whilst retaining RNA integrity.

   Tailored surface lipids combined with pH dependant silicon/RNA bond dissolution maximise transfection efficiency.

   The versatility of particle size, surface charge and the addition of surface ligands enable passive or active cell targeting and multiple administration routes.

RNA Delivery

The Fundamental Challenge

Critical to the success of RNA-based therapeutics is the delivery system. It needs to stabilise and protect the RNA molecules from degradation, and it needs to ensure delivery to the target cell’s cytoplasm in sufficient quantities to elicit the desired cellular response with little or no adverse effects or accumulation.

Lipid nanoparticles (LNPs), the current mainstay, are fragile and can allow RNA to detach as their electrostatic potential deteriorates, limiting systemic survival and necessitating ultra-cold storage and transportation.

The high proportion of cationic lipids used in LNPs can create toxicity when oxidised and the prevalence of polyethylene glycol (PEG) can trigger antibodies (αPEG Abs), which recognize PEG as foreign.

RNA Delivery

The Fundamental Challenge

Critical to the success of RNA-based therapeutics is the delivery system. It needs to stabilise and protect the RNA molecules from degradation, and it needs to ensure delivery to the target cell’s cytoplasm in sufficient quantities to elicit the desired cellular response with little or no adverse effects or accumulation.

Lipid nanoparticles (LNPs), the current mainstay, are fragile and can allow RNA to detach as their electrostatic potential deteriorates, limiting systemic survival and necessitating ultra-cold storage and transportation.

The high proportion of cationic lipids used in LNPs can create toxicity when oxidised and the prevalence of polyethylene glycol (PEG) can trigger antibodies (αPEG Abs), which recognize PEG as foreign.

Bio-Courier® Technology

The Solution

SiSaf’s Bio-Courier technology addresses the challenges of lipid nanoparticles by stabilizing both lipids and RNA through a bioabsorbable silicon matrix

   Silicon’s positive charge and high ζ-potential electrostatically bind and condense RNA preventing the premature disassociation of RNA and reducing the reliance on cationic lipids.

   High volumes of tightly condensed RNA are electrostatically bonded to the silicon matrix, protecting them from hydrolysis to prolong their systemic survival.

    The structural integrity of the Silicon metalloid prevents physical collapse of the particle permitting lyophilisation whilst retaining RNA integrity.

   Tailored surface lipids combined with pH dependant silicon/RNA bond dissolution maximise transfection efficiency.

   The versatility of particle size, surface charge and the addition of surface ligands enable passive or active cell targeting and multiple administration routes.

Bio-Courier vs LNP

Bio-Courier vs LNP

Publications